Published in Clin Transplant on August 01, 2004
Validation of anti-aging drugs by treating age-related diseases. Aging (Albany NY) (2009) 2.01
Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging (Albany NY) (2012) 1.79
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant (2010) 1.68
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol (2011) 1.46
Rapalogs in cancer prevention: anti-aging or anticancer? Cancer Biol Ther (2012) 1.40
Immunosuppressants in cancer prevention and therapy. Oncoimmunology (2013) 1.17
Rejuvenating immunity: "anti-aging drug today" eight years later. Oncotarget (2015) 1.13
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol (2008) 1.12
Roles of the immune system in skin cancer. Br J Dermatol (2011) 1.12
Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin. Cancer Biol Ther (2014) 1.08
Progeria, rapamycin and normal aging: recent breakthrough. Aging (Albany NY) (2011) 1.06
How to save Medicare: the anti-aging remedy. Aging (Albany NY) (2012) 1.04
HPV-related cancers after solid organ transplantation in the United States. Am J Transplant (2013) 1.03
Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? Aging (Albany NY) (2012) 1.02
Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol (2010) 0.98
Toll-like receptors: role in dermatological disease. Mediators Inflamm (2010) 0.93
Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. Elife (2016) 0.92
Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant (2008) 0.86
Immunostimulatory activity of lifespan-extending agents. Aging (Albany NY) (2013) 0.85
Donor transmitted and de novo cancer after liver transplantation. World J Gastroenterol (2014) 0.85
Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype. Nephrol Dial Transplant (2012) 0.83
Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder. Pediatr Transplant (2012) 0.81
PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas. Am J Transplant (2013) 0.81
Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant (2012) 0.80
Randomized exposure-controlled trials; impact of randomization and analysis strategies. Br J Clin Pharmacol (2007) 0.79
Distinct innate immune gene expression profiles in non-melanoma skin cancer of immunocompetent and immunosuppressed patients. PLoS One (2012) 0.79
Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? Clin Dev Immunol (2013) 0.79
Genetic polymorphisms of mTOR and cancer risk: a systematic review and updated meta-analysis. Oncotarget (2016) 0.78
Transplantation: Sirolimus for secondary SCC prevention in renal transplantation. Nat Rev Nephrol (2012) 0.78
Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinoma. JAAD Case Rep (2015) 0.78
Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. Transpl Int (2016) 0.78
Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol (2015) 0.77
Forever young? Exploring the link between rapamycin, longevity and cancer. Cell Cycle (2012) 0.77
Anorectal human papillomavirus: current concepts. Yale J Biol Med (2014) 0.77
Immune profiling and cancer post transplantation. World J Nephrol (2015) 0.77
Clinical and Economic Consequences of Early Cancer after Kidney Transplantation in Contemporary Practice. Transplantation (2016) 0.75
Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now? World J Gastroenterol (2015) 0.75
A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation. Ther Drug Monit (2017) 0.75
Skin cancer in immunosuppressed transplant patients: Vigilance matters. World J Hepatol (2015) 0.75
Monitoring alloimmune response in kidney transplantation. J Nephrol (2016) 0.75
Invasive squamous cell bladder cancer of the ureterovesical junction in a renal transplant patient: a case report. J Surg Case Rep (2017) 0.75
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73
Very long-term follow-up of living kidney donors. Transpl Int (2012) 1.61
Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int (2011) 1.53
Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients. J Clin Virol (2007) 1.49
Lithium-induced nephropathy: Rate of progression and prognostic factors. Kidney Int (2003) 1.48
Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation (2004) 1.45
The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation (2004) 1.44
Clinical and immunological features of very long-term survivors with a single renal transplant. Transpl Int (2012) 1.42
Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol (2010) 1.31
Liver transplantation from non-heart-beating donors: current status and future prospects. Liver Transpl (2004) 1.22
Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med (2006) 1.20
Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation (2006) 1.14
Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant (2002) 1.11
Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation (2005) 1.11
Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant (2005) 1.04
A clinical scoring system highly predictive of long-term kidney graft survival. Kidney Int (2010) 1.03
Groove pancreatitis. A mini-series report and review of the literature. JOP (2011) 1.00
Vitamin D status and outcomes after renal transplantation. J Am Soc Nephrol (2013) 0.97
Incidence of renal and liver rejection and patient survival rate following combined liver and kidney transplantation. Am J Transplant (2003) 0.97
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int (2005) 0.97
Angioedema in renal transplant recipients on sirolimus. Dermatology (2007) 0.95
Renal cell carcinoma of the grafted kidney: how to improve screening and graft tracking. Transplantation (2004) 0.95
Celiac artery occlusion encountered during pancreatic resection: a case report. Ann R Coll Surg Engl (2007) 0.94
Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation (2003) 0.94
Pretransplant identification of acute rejection risk following kidney transplantation. Transpl Int (2013) 0.92
Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol (2006) 0.92
The incidence and importance of bacterial contaminants of cadaveric renal perfusion fluid. Transpl Int (2004) 0.91
New computerized color image analysis for the quantification of interstitial fibrosis in renal transplantation. Transplantation (2011) 0.90
Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation (2005) 0.90
Non-heart-beating donor porcine livers: the adverse effect of cooling. Liver Transpl (2005) 0.90
Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy. Transplantation (2011) 0.90
Examination of serum miRNA levels in kidney transplant recipients with acute rejection. Transplantation (2014) 0.88
Thrombotic microangiopathy and hypothermia in an HIV-positive patient: importance of cytomegalovirus infection. Scand J Infect Dis (2004) 0.87
Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial. Transplantation (2003) 0.86
Cholecalciferol supplementation does not protect against renal allograft structural and functional deterioration: a retrospective study. Transplantation (2011) 0.85
Blocking porcine sialoadhesin improves extracorporeal porcine liver xenoperfusion with human blood. Xenotransplantation (2013) 0.83
Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant (2002) 0.82
Executive Summary of IPITA-TTS Opinion Leaders Report on the Future of β-Cell Replacement. Transplantation (2016) 0.82
Poor long-term outcome in second kidney transplantation: a delayed event. PLoS One (2012) 0.81
Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation (2005) 0.81
Renal-transplant recipients and sun protection. Transplantation (2004) 0.80
Long-term outcome of third kidney transplants. Nephrol Dial Transplant (2007) 0.80
Impact of surgical procedures and complications on outcomes of third and subsequent kidney transplants. Transplantation (2007) 0.80
An unusual recurrence of crescentic nephritis after renal transplantation for IgA nephropathy. Am J Kidney Dis (2002) 0.79
Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement. Transplantation (2016) 0.79
Influence of albumin supplementation on tacrolimus and cyclosporine therapy early after liver transplantation. Liver Transpl (2002) 0.79
Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. Transplant Res (2013) 0.78
Pancreas transplantation: solid organ and islet. Cold Spring Harb Perspect Med (2014) 0.77
An alternative approach to estimate age-related mortality of kidney transplant recipients compared to the general population: results in favor of old-to-old transplantations. Transpl Int (2013) 0.77
Late introduction of sirolimus induces anemia in renal transplant recipients. Transplantation (2007) 0.77
Acute renal failure following allogeneic hematopoietic cell transplantation: incidence, outcome and risk factors. Saudi J Kidney Dis Transpl (2011) 0.77
Alemtuzumab: right drug, right dose? Transpl Int (2011) 0.77
Current state of abdominal wall transplantation. Curr Opin Organ Transplant (2016) 0.76
HDAF transgenic pig livers are protected from hyperacute rejection during ex vivo perfusion with human blood. Xenotransplantation (2002) 0.76
Less pessimistic long-term results for patients with cytomegalovirus disease. Clin Infect Dis (2008) 0.76
Single graft loss in dual renal transplant recipients: impact of graft placement on recipient outcomes. Transpl Int (2011) 0.76
Calibration of ultrasound backscatter temperature imaging for high-intensity focused ultrasound treatment planning. Ultrasound Med Biol (2013) 0.76
Parvovirus B19-related anaemia after renal transplantation. Scand J Infect Dis (2004) 0.76
Long-term kidney graft survival by delayed T cell ablative treatment in rhesus monkeys. Transplantation (2002) 0.76
Prognostic indicators following curative pancreatoduodenectomy for pancreatic carcinoma: A retrospective multivariate analysis of a single centre experience. J BUON (2016) 0.75
Unusual post-transplantation recurrence of focal segmental glomerulosclerosis which resolved with cyclosporine but not with sirolimus. Transpl Int (2005) 0.75
Reply to Letter: "Utilization of Small Pediatric Donors Including Infants for Pancreas and Kidney Transplantation: Exemplification of the Surgical Technique and Surveillance". Ann Surg (2015) 0.75
Renal function and cardiovascular outcomes after living donor nephrectomy in the UK: quality and safety revisited. BJU Int (2013) 0.75
Correction to 'Magnetic targeting of microbubbles against physiologically relevant flow conditions'. Interface Focus (2016) 0.75
Should routine pyeloureterostomy be advocated in adult kidney transplantation? A prospective study of 283 recipients. J Urol (2010) 0.75
The abdominal wall transplant as a sentinel skin graft. Curr Opin Organ Transplant (2016) 0.75
Donor lymphocyte infusion for late relapse followed by kidney transplantation for end-stage renal failure after allogeneic bone marrow transplantation for chronic myeloid leukemia. Transplantation (2003) 0.75
Vessel rejection secondary to human leucocyte antigen antibodies directed against the arterial conduit following pancreas transplantation from a separate donor. Transpl Int (2014) 0.75
App to reality: snapshot validation of the US Pancreas Donor Risk Index in a UK center. J Surg Res (2013) 0.75
How well do pre- and peritransplant variables predict the long-term results of kidney transplantation? Clin Transpl (2008) 0.75
[Renal transplantation: ethical issues]. Nephrol Ther (2012) 0.75
Veno-occlusive disease of the liver in renal transplant patients. Nephrol Dial Transplant (2003) 0.75
Severe human herpesvirus-8 primary infection in a renal transplant patient successfully treated with anti-CD20 monoclonal antibody. Blood (2006) 0.75
Influence of anemia on patient and graft survival after renal transplantation: results from the French DIVAT cohort. Transplantation (2014) 0.75